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Prevention of cervical cancer in HIV-
seropositive women from developing
countries: a systematic review protocol
Witness Mapanga1,6* , Ahmed Elhakeem2, Shingairai A. Feresu1, Fresier Maseko3 and Tsungai Chipato4,5
Abstract
Background: Over 85% of cervical cancer cases and deaths occur in developing countries. HIV-seropositive women
are more likely to develop precancerous lesions that lead to cervical cancer than HIV-negative women. However,
the literature on cervical cancer prevention in seropositive women in developing countries has not been reviewed.
The aim of this study is to systematically review cervical cancer prevention modalities available for HIV-seropositive
women in developing countries.
Methods/design: This protocol was developed by following the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses Protocols (PRISMA-P) statement, and the systematic review will be reported in accordance with
the PRISMA guidelines. Embase, MEDLINE, PubMed, CINAHL and Cochrane Library will be searched from inception
up to date of final search, and additional studies will be located through citation and reference list tracking. Eligible
studies will be randomised controlled trials, prospective and retrospective cohort studies, case-control and cross-
sectional studies carried out in developing countries. Studies will be included if they are published in English and
examine cervical cancer prevention modalities in HIV-seropositive women. Results will be summarised in tables and,
where appropriate, combined using meta-analysis.
Discussion: This review will address the gap in evidence by systematically reviewing the published literature on the
different prevention modalities being used to prevent cervical cancer in HIV-seropositive women in developing
countries. The findings may be used to inform evidence-based guidelines for prevention of cervical cancer in
seropositive women as well as future research.
Systematic review registration: PROSPERO CRD42017054678.
Keywords: Developing countries, Cervical cancer, HIV, Prevention
Background
Cervical cancer morbidity and mortality constitutes a
growing burden in developing countries like Zimbabwe,
Kenya, India, Botswana and South Africa; concern has
shifted to how much can be done to prevent this public
health challenge in all women with a lifetime risk ap-
proaching 1 in 20 in some developing settings [1]. A sys-
tematic review on the cervical cancer screening and
prevention indicated that about 88% of all cervical can-
cer worldwide occurs in developing countries where
there is very limited allocated resources to prevent and
treat cervical cancer [1]. Research has shown that one
has to be infected with human papilloma virus (HPV) to
develop cervical cancer, but HPV alone does not fully
explain cervical cancer epidemiology hence a number of
cofactors associated [2, 3].
With the adverse of HIV in most of these developing
countries especially those in sub-Saharan Africa, the
burden of cervical cancer is increasing. HIV, which is a
risk factor for cervical cancer, lowers women’s immune
system, making them more susceptible to HPV infection
[4–7]. Globally, 1 to 2% of HIV-negative women develop
cervical intraepithelial neoplasia (CIN) stages 2 and 3
annually whilst HIV-positive women are at 10% more
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prone to developing CIN stages 2 and 3 [8]. The adverse
of HIV/AIDS in most developing countries has resulted
in high cervical cancer prevalence and because of this;
cervical cancer has been classified as an AIDS-defining
disease [5–7].
HIV-seropositive women have been found to be at
higher risk of HPV infection due to their immune com-
promised status and that they are 2 to 12 times more
likely to develop cervical precancerous lesions that lead
to cervical cancer than HIV-negative women [5, 6]. In a
case-control study in South Africa, HIV-seropositive
women infected with HPV had a more than 40-fold
higher risk of developing cervical squamous intraepithe-
lial lesions compared to women who are both HIV and
HPV negative [7].
Although cervical cancer screening in HIV-
seropositive women has been found to reduce cervical
cancer morbidity [8–10], challenges and constraints still
exists in developing countries that make it difficult for
cervical cancer screening to be available. Most develop-
ing countries do not have adequate or well-equipped la-
boratories, good quality control, qualified pathologists
and cytotechnicians who are able to analyse and inter-
pret laboratory specimen hence cervical cancer screen-
ing using HPV DNA, and Pap smear might not be
available or it is expensive [10–12]. In cases where Pap
smear or visual inspection with acetic acid (VIA) is
available, it is mostly found in big urban clinics and hos-
pitals and comes with a cost that many women cannot
afford as well as being on waiting lists for months.
Therefore, what is lacking in most developing countries
is a systematic and organised population-based screening.
This lack of organised and systematic population-based
screening has resulted in cervical cancer screening among
HIV-seropositive women to be poor, uncoordinated and
sometimes undocumented. With research to test the effi-
ciency of HPV vaccines on HIV-positive women currently
underway, little is known on how effective it is in prevent-
ing cervical cancer in HIV-positive women [10]. The
current WHO guidelines on the prevention of cervical
cancer include cytology, VIA and HPV test. Besides the
current research, most developing countries are yet to
offer HPV vaccination, and this might not happen anytime
soon because of lack of financial resources and technical
expertise. Therefore, we aimed to review the available mo-
dalities used in the prevention of cervical cancer in HIV-
seropositive women in developing countries so as to an-
swer the following questions:
 Are cervical cancer prevention modalities being used
for HIV-seropositive women different between
countries?
 Have cervical cancer prevention modalities being used
for HIV-seropositive women improved over time?
 Are cervical cancer prevention modalities being used
for HIV-seropositive women effective in preventing
cervical cancer?
Methods/design
The development and reporting of this protocol was
guided by the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) Protocols
(PRISMA-P) statement [13], and the systematic review
will be carried out in accordance with the PRISMA
guidelines [14].
Protocol registration
This review protocol was registered with PROSPERO
database (registration number: CRD42017054678) [15].
Studies’ eligibility criteria
Studies will be included if
 The sample/population of interest are women
 Cervical cancer prevention methods for HIV-
positive women (such as Pap smear, visual inspec-
tion with acetic acid, HPV DNA testing and HPV
vaccination among others) are key outcomes
 HIV and cervical cancer prevention modalities are
considered being independent and outcome
variables, respectively
 Description, effect or impact of the prevention
modality on HIV-seropositive women is an outcome
 Published in peer-reviewed journals
 Done in or for countries or regions considered to be
developing countries by United Nations [16]
 They are randomised controlled trials and
observational study designs—prospective cohorts,
retrospective cohorts, case-control and cross-
sectional
 Reported in English language
 Prospective cohort studies have a defined length of
follow-up. Length of follow-up will be used to assess
for the quality of the outcomes.
Studies will not be excluded based on length of follow-
up. However, follow-up rates will be used to give scores
to the quality of the outcomes. Follow-up rates of less
than 60% are going to be considered as having limited
validity especially when the reasons for loss are related
to both exposure and outcome status [17]
In cases of studies done across countries, that are de-
veloped and developing, the team will extract results for
developing countries from these where possible and may
contact study authors if not available from paper. All
studies will be included, and sample sizes will be used to
assess quality and inform interpretation of findings. The
reviewers’ assumptions are that studies with smaller
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samples might not provide additional value in terms
of high quality evidence [18]. Reviews and studies
looking at cervical cancer in general and those with
unrepresentative samples will be excluded. Unrepre-
sentative samples (looking at HIV-positive women,
controls and sampling criteria) will be identified
through performing non-parametric tests on geo-
graphical and demographical representation of the
sample against that of the population.
Search strategy
The search system through the online databases will be
based on the OVID search system. Key words will be
used and will be supplemented by free-text terms (syno-
nyms) of keywords to locate all the potential eligible arti-
cles. The search will be up to date of the final search.
The following databases will be searched, PubMed (via
the PubMed/MEDLINE interface using the “PICO” op-
tion), Cochrane (via The Cochrane Library using MeSH
terms and qualifiers), CINAHL (via the EBSCO interface
using key words), Embase and MEDLINE (via the
OvidSP interface using key words (Table 1)). Truncation
commands (root word) and proximity operators (words
which will be within a chosen distance of each other)
and Boolean logic operators (OR and AND) will be used
as well (Table 2). To improve the efficiency of the final
search, preliminary trials with search terms will be con-
ducted. Citation and reference tracking will be used to
search additional papers to add to the electronic data-
base search, as shown in the PRISMA flow chart (Fig. 1).
Study selection
Merging of the results of the database searches will be
done and two independently working researchers (from
among WM, FM, SF and TC), will screen for abstracts.
The full-text screening form (see Additional file 1) will
be used to select potentially eligible papers. The papers
will be double-screened and reasons for exclusions will
be documented. Through discussions, disagreements
and other issues pertaining to the screening process will
be resolved among WM, AE, FM, SF and TC.
Data extraction
Data will be double extracted by WM, FM, SF, TC, and
discrepancies and disagreements will be resolved
through discussions. The data extraction form (see Add-
itional file 2) will be pretested/piloted on a few selected
studies and will be adjusted accordingly for its appropri-
ateness. The following data will be extracted from the
included studies: publication year of the study, title of
the study, study design, study setting (country/region),
sample size, exposures and outcomes, all statistics such
as descriptive, odds/risk ratios, logistic and linear
regression and confounders included in the analysis will
be extracted.
Quality assessment
A modified version of the Newcastle-Ottawa Quality As-
sessment Scale [19], see Additional file 3, will be used to
ascertain the quality of all included studies during data ex-
traction. Quality of the included studies will be based on
the following: study design used to measure cervical can-
cer prevention and or screening, focus of research and key
findings (that is if study is describing prevention modal-
ities or comparing two or more prevention modalities),
representativeness of participants and length of follow-up.
Studies included in the review will be categorised into
three groups, RCTs, observational studies with a control
group and observational studies without a control group.
For RCT studies, we will assess whether (1) randomization
of participants is reported, (2) all participants who entered
the study would have been accounted for in the analysis, (3)
participants were analysed in the groups they were rando-
mised to, (4) blinded outcome assessment was used, (5)
power calculation information was provided, (6) baseline
characteristics of study groups were balanced at the start of
Table 1 MEDLINE and Embase search strategy via OvidSP
Search terms
1. cervi* canc*.mp. [mp = title, abstract, full text, caption text]
2. cervi* neoplas*.mp. [mp = title, abstract, full text, caption text]
3. cervi* carcinom*.mp. [mp = title, abstract, full text, caption text]
4. cervi* dysplas*.mp. [mp = title, abstract, full text, caption text]
5. cervi* intraepithelial neoplas*.mp. [mp= title, abstract, full text, caption text]
6. prevent* or screen*.mp. [mp = title, abstract, full text, caption text]
7. pap smear*.mp. [mp = title, abstract, full text, caption text]
8. colposcopy.mp. [mp = title, abstract, full text, caption text]
9. hpv adj3 vaccin*.mp. [mp = title, abstract, full text, caption text]
10. HIV positive.mp. [mp = title, abstract, full text, caption text]
11. hiv seropositiv*.mp. [mp = title, abstract, full text, caption text]
12. hiv.mp. [mp = title, abstract, full text, caption text]
13. developing countr*.mp. [mp = title, abstract, full text, caption text]
14. underdeveloped countr*.mp. [mp = title, abstract, full text, caption text]
15. low income countr*.mp. [mp = title, abstract, full text, caption text]
16. low resource countr*.mp. [mp = title, abstract, full text, caption text]
17. low resource setting*.mp. [mp = title, abstract, full text, caption text]
18. developing countries.mp. [mp = title, abstract, full text, caption text]
19. 1 or 2 or 3 or 4 or 5
20. 6 or 7 or 8 or 9
21. 10 or 11 or 12
22. 13 or 14 or 15 or 16 or 17 or 18
23. 19 and 20 and 21 and 22
Mapanga et al. Systematic Reviews  (2017) 6:91 Page 3 of 7
the study, and, in case were there was imbalance, adjusted
for the imbalance was done in the analyses (Table 3).
Observational studies with a control group will be
assessed to see whether (1) participants, both groups,
were stratified for the cervical cancer prevention or
screening method under review, (2) if groups were not
stratified for prevention and screening methods and the
distribution was unbalanced, we will assess whether the
outcomes were adjusted for (Table 4).
For observational studies without a control group,
we will assess whether (1) the study population was a
consecutive cohort of participants, (2) included partic-
ipants have fulfilled predefined criteria, (3) study
design (prospective or retrospective) information was
given (Table 5).
For the outcome measures in all study groups, we will
assess whether (1) a predefined outcome measure was
defined and (2) any method or cervical cancer preven-
tion or screening was used or information on its applica-
tion was given (Table 6).
Screening of search results, quality examination and
extraction of relevant data, will be carried out by two in-
dependently working researchers. Any discrepancies and
disagreements that arise during the review study will be
resolved through discussion. The average of the two re-
viewers will be the quality score for each study, where a
range of zero (lowest quality) to five (highest quality)
will be used. Studies will not be excluded based on qual-
ity rating but quality results will be included in the syn-
thesis of the findings.
Synthesis
Results of this review are going to be synthesised in two
forms, that is, narrative synthesis and meta-analysis [20].
The narrative synthesis will summarise the results and
characteristics of the included studies through the use of
tables. Where sufficient consistency is found in the
reporting of the methods and results across different
studies, meta-analysis will be used to combine the nu-
merical findings, e.g., odds/ratio ratios, daily-adjusted life
years (DALY) of the effect or impact of the prevention
modality on HIV-seropositive women so as to provide
adequate estimates.
Random-effects aggregate data meta-analysis will be
used to combine the findings from the different studies
which will be included in the review. If included studies
have sufficient details to extract data of participants’ ages
Table 2 Techniques to be used in the online databases search
Techniques Description Example
Free-text
synonyms of
keyword
search
All known synonyms of
the keyword in both British
and US spellings
Cervical cancer synonyms:
cervical carcinomas, cervix
neoplasms, cervical
intraepithelial neoplasia,
cervix dysplasia etc.
Truncation
commands
Using the root word to
capture alternative word
endings
Cervi* carcinom* searches
for words such as cervical
carcinoma, cervix
carcinomas etc.
Proximity
operators
Operators used will be
Adj3 in OvidSP interface
hpv adj3 vaccin*
Boolean logic
operators
‘OR’ and ‘AND’ will be the
two commands to be
used.
‘OR’ is used to locate
articles with at least one of
the search terms.
‘AND’ is to be used near
the end of a search so as
to combine results of
different search concepts.
prevent* or screen* OR
pap smear* OR colposcopy
OR hpv adj3 vaccin*
(prevent* or screen* OR
pap smear* OR colposcopy
OR hpv adj3 vaccin*) AND
(HIV positive OR hiv
seropositiv* OR hiv)
Fig. 1 PRISMA review flow chart
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or duration of HIV infection, then subgroup analysis to
answer specific questions about different participants’
groups will be performed. Estimates during analysis will
be presented in forest plots and tables. The meta-
analysis will be run using the STATA Statistical package.
Data entry will be done by the two independent re-
viewers so as to limit typing errors.
The meta-analysis will also be used for the review’s
sensitivity analysis and assessment of bias. Judgement
and risk of bias table will be used through a risk of bias
tool specific for each included study. Through judge-
ment, reviewers will assess the risk of bias as follows:
‘low risk’, ‘high risk’ or ‘unclear risk’ when there is lack of
information on bias. Funnel plots of risk of bias will be
created using RevMan software and t test applicable at
probability of 95% will be performed for statistical sig-
nificance. Heterogeneity between the analysed studies
will be assessed using Higgins and Thompson’s I2 statis-
tic [21, 22]. An I2 statistic of 0% indicates no observed
heterogeneity and larger values indicate increasing het-
erogeneity, and this will be significant at p value less
than or equal to 0.05.
Table 3 Randomised clinical trials quality assessment checklist
Assessment criteria Studies
fulfilling
criteria
Studies not
fulfilling criteria
Randomization of participants is
reported
All participants who entered the study
would have been accounted for in the
analysis
Participants were analysed in the groups
they were randomized to
Blinded outcome assessment was used
Power calculation information was
provided
Baseline characteristics of study groups
were balanced or adjustment for the
imbalance in analyses
Table 4 Observational studies with a control group quality
assessment checklist
Assessment criteria Studies
fulfilling
criteria
Studies not
fulfilling
criteria
Studies
not
applicable
Assessment of participants’ on
admission to study
Assessment of prevention
method under review
Participants were stratified for the
cervical cancer prevention or
screening method under review
Ascertainment of cervical cancer
and HIV status, prospectively from
participants through diagnosis,
laboratory tests and blood tests
Ascertainment of cervical cancer
and HIV status, retrospectively
from participants through
diagnosis, laboratory tests and
blood tests
Complete follow-up—all subjects
accounted for
Subjects lost to follow up unlikely
to introduce bias (≥75% follow-
up or description provided of
those lost
If groups were not stratified for
prevention and screening
methods and the distribution was
unbalanced, were outcomes
adjusted for
Table 5 Observational studies without a control group quality
assessment checklist
Assessment criteria Studies
fulfilling
criteria
Studies not
fulfilling criteria
Study population was a consecutive
cohort of participants
Included participants have fulfilled
predefined criteria
Study design information given
Table 6 Outcome measures’ quality assessment checklist
Methods of
screening/prevention
Assessment
criteria
Studies
fulfilling
criteria
Studies not
fulfilling criteria
Pap smear Clinical
definition
Technical
investigation
Definition
of abnormal results
Visual inspection
with acetic acid
Clinical definition
Technical
investigation
Definition of
abnormal results
HPV vaccination Clinical definition
Technical
investigation
Definition of
abnormal results
Other prevention/
screening methods
Clinical definition
Technical
investigation
Definition of
abnormal results
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Reporting
This systematic review and its findings will be reported
in accordance with the PRISMA statement.
Conclusions
The evidence generated from this review will be used to
address the gaps that might exist in the prevention and
screening of cervical cancer in HIV-seropositive women
as well as informing future research, cervical cancer pol-
icies and cervical cancer interventions. The strengths
and limitations for this review will be considered, and
the review findings will be discussed in the context of
other reviews and evidence that are relevant.
Additional files
Additional file 1: Full-text screening form. This form will be used for the
screening of potentially eligible studies to be included in the review.
(DOCX 15 kb)
Additional file 2: Data extraction form. This form will be used to extract
relevant data such as exposure and outcome and statistics from the
included studies. (DOCX 18 kb)
Additional file 3: Quality assessment form. This form will be used for
grading the quality of studies included in the review. It is a modified/
amended version of the Newcastle-Ottawa Quality Assessment Scale.
(DOCX 21 kb)
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